Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab plus Nab-paclitaxel vs Paclitaxel in Advanced Gastric Cancer
NCT04435652Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of iparomlimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
iparomlimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04435652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435652.